NHS Framework Agreement for Human Albumin & Normal and Anti-D Immunoglobulin
NHS England · awarded 19 December 2024 · delivered in Scotland
£905.2m
Award value
£905,187,090
6
Suppliers
Recorded as a large business
31 Dec 2027
Runs until
from 1 Apr 2025
Who
| Buyer | NHS England Runcorn |
|---|---|
| Suppliers |
Bio Products Laboratory Ltd CSL Behring UK Ltd Grifols UK Ltd. LFB Octapharma Limited Takeda UK Ltd |
| Category | goods |
| Classification | Immunoglobulins CPV 33651520 |
| Notice published | 20 January 2025 |
What it is for
NHS Framework Agreement for Human Albumin & Normal and Anti-D Immunoglobulin Offer reference number: CM/PHS/23/5703 The period of the framework is 1 April 2025 to 31 December 2027 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 15 months. The total maximum framework agreement duration, including extension options, will be no more than 48 months.
Read the original award notice on Contracts Finder →
Other contracts from this buyer
1269 awards on file, worth £50.2bn.
| Awarded | What for | Buyer | Supplier | Value |
|---|---|---|---|---|
| 4 Mar 2026 | New Hospital Programme - Hospital 2.0 Alliance (H2A) FrameworkEngland | NHS England | Willmott Dixon Construction Limited +9 | £37.0bn |
| 24 Mar 2025 | NHS Framework Agreement for Branded Medicines - Proprietary Category TenderEast Midlands | NHS England | CSL Behring UK Ltd +71 | £1.2bn |
| 1 Jul 2025 | NHS Branded Medicines Tranche B - MAE & NOFE - 1 September 2025 | NHS England | Biogen +20 | £986.3m |
| 19 Dec 2024 | NHS Framework Agreement for Human Albumin & Normal and Anti-D ImmunoglobulinScotland | NHS England | CSL Behring UK Ltd +5 | £905.2m |
| 31 May 2024 | NHS Framework - Blood Disorders including Haemophilia A and B - July 2024East Midlands | NHS England | Pfizer Ltd +8 | £765.0m |
Everything NHS England has awarded →
Other contracts won by this supplier
5 awards on file, worth £2.9bn.
| Awarded | What for | Buyer | Supplier | Value |
|---|---|---|---|---|
| 24 Mar 2025 | NHS Framework Agreement for Branded Medicines - Proprietary Category TenderEast Midlands | NHS England | CSL Behring UK Ltd +71 | £1.2bn |
| 19 Dec 2024 | NHS Framework Agreement for Human Albumin & Normal and Anti-D ImmunoglobulinScotland | NHS England | CSL Behring UK Ltd +5 | £905.2m |
| 31 May 2024 | NHS Framework - Blood Disorders including Haemophilia A and B - July 2024East Midlands | NHS England | Pfizer Ltd +8 | £765.0m |
| 1 Jan 2025 | CSL Behring - Blood Disorder Treatment products (inc Haemophilia A & B)East of England | Norfolk and Norwich University Hospitals NHS… | CSL BEHRING UK LIMITED | £416k |
| 12 Jun 2026 | Beriplex | The Christie NHS Foundation Trust | CSL BEHRING UK LIMITED | £12k |